William Blair Lifts Earnings Estimates for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – Research analysts at William Blair increased their Q1 2025 EPS estimates for Krystal Biotech in a report issued on Wednesday, February 19th. William Blair analyst S. Corwin now anticipates that the company will earn $1.47 per share for the quarter, up from their prior estimate of $1.25. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.64 EPS, Q3 2025 earnings at $1.82 EPS, Q4 2025 earnings at $2.11 EPS, FY2025 earnings at $7.04 EPS and FY2026 earnings at $9.97 EPS.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter last year, the business earned $0.30 EPS.

A number of other brokerages have also issued reports on KRYS. Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $210.00.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $186.89 on Monday. The company has a 50 day simple moving average of $157.85 and a 200 day simple moving average of $175.26. The firm has a market cap of $5.38 billion, a PE ratio of 62.51 and a beta of 0.84. Krystal Biotech has a 1 year low of $125.85 and a 1 year high of $219.34.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in Krystal Biotech during the 4th quarter valued at $95,000. Palisades Investment Partners LLC lifted its stake in Krystal Biotech by 9.3% during the 4th quarter. Palisades Investment Partners LLC now owns 40,479 shares of the company’s stock valued at $6,341,000 after acquiring an additional 3,436 shares in the last quarter. Woodline Partners LP lifted its stake in Krystal Biotech by 23.0% during the 4th quarter. Woodline Partners LP now owns 221,102 shares of the company’s stock valued at $34,638,000 after acquiring an additional 41,287 shares in the last quarter. Soleus Capital Management L.P. lifted its stake in Krystal Biotech by 65.2% during the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock valued at $56,144,000 after acquiring an additional 141,400 shares in the last quarter. Finally, ProShare Advisors LLC lifted its stake in Krystal Biotech by 28.6% during the 4th quarter. ProShare Advisors LLC now owns 8,848 shares of the company’s stock valued at $1,386,000 after acquiring an additional 1,967 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).